| Species differences in pharmacokinetics and pharmacodynamics PL Toutain, A Ferran, A Bousquet-Mélou Comparative and Veterinary Pharmacology, 19-48, 2010 | 294 | 2010 |
| En Route towards European Clinical Breakpoints for Veterinary Antimicrobial Susceptibility Testing: A Position Paper Explaining the VetCAST Approach PL Toutain, A Bousquet-Mélou, P Damborg, AA Ferran, D Mevius, ... Frontiers in microbiology 8, 2344, 2017 | 152 | 2017 |
| Impact of early versus later fluoroquinolone treatment on the clinical; microbiological and resistance outcomes in a mouse-lung model of Pasteurella multocida infection AA Ferran, PL Toutain, A Bousquet-Mélou Veterinary microbiology 148 (2), 292-297, 2011 | 76 | 2011 |
| Veterinary Medicine Needs New Green Antimicrobial Drugs PL Toutain, AA Ferran, A Bousquet-Melou, L Pelligand, P Lees Frontiers in Microbiology 7, 1196, 2016 | 73 | 2016 |
| The pharmacokinetic/pharmacodynamic paradigm for antimicrobial drugs in veterinary medicine: Recent advances and critical appraisal PL Toutain, L Pelligand, P Lees, A Bousquet‐Mélou, AA Ferran, ... Journal of Veterinary Pharmacology and Therapeutics 44 (2), 172-200, 2021 | 69 | 2021 |
| Pharmacokinetic/pharmacodynamic analysis of the influence of inoculum size on the selection of resistance in Escherichia coli by a quinolone in a mouse thigh bacterial … AA Ferran, AS Kesteman, PL Toutain, A Bousquet-Mélou Antimicrobial agents and chemotherapy 53 (8), 3384-3390, 2009 | 65 | 2009 |
| Influence of inoculum size and marbofloxacin plasma exposure on the amplification of resistant subpopulations of Klebsiella pneumoniae in a rat lung infection model AS Kesteman, AA Ferran, A Perrin-Guyomard, M Laurentie, P Sanders, ... Antimicrobial agents and chemotherapy 53 (11), 4740-4748, 2009 | 61 | 2009 |
| Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin A Ferran, V Dupouy, PL Toutain, A Bousquet-Mélou Antimicrobial agents and chemotherapy 51 (11), 4163-4166, 2007 | 61 | 2007 |
| Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients? D Concordet, P Gandia, JL Montastruc, A Bousquet-Mélou, P Lees, ... Clinical pharmacokinetics, 1-7, 2019 | 42 | 2019 |
| Low or High Doses of Cefquinome Targeting Low or High Bacterial Inocula Cure Klebsiella pneumoniae Lung Infections but Differentially Impact the Levels of Antibiotic Resistance … MV Vasseur, M Laurentie, JG Rolland, A Perrin-Guyomard, J Henri, ... Antimicrobial agents and chemotherapy 58 (3), 1744-1748, 2014 | 42 | 2014 |
| In vitro Degradation of Antimicrobials during Use of Broth Microdilution Method Can Increase the Measured Minimal Inhibitory and Minimal Bactericidal Concentrations EA Lallemand, MZ Lacroix, PL Toutain, S Boullier, AA Ferran, ... Frontiers in Microbiology 7, 2016 | 41 | 2016 |
| Impact of Timing and Dosage of a Fluoroquinolone Treatment on the Microbiological, Pathological, and Clinical Outcomes of Calves Challenged with Mannheimia haemolytica G Lhermie, AA Ferran, S Assié, H Cassard, F El Garch, M Schneider, ... Frontiers in Microbiology 7, 2016 | 38 | 2016 |
| Use of Monte Carlo simulation to determine pharmacodynamic cutoffs of amoxicillin to establish a breakpoint for antimicrobial susceptibility testing in pigs JF Rey, CM Laffont, S Croubels, P De Backer, C Zemirline, E Bousquet, ... American Journal of Veterinary Research 75 (2), 124-131, 2014 | 38 | 2014 |
| Pharmacokinetic/pharmacodynamic assessment of the effects of parenteral administration of a fluoroquinolone on the intestinal microbiota: Comparison of bactericidal activity at … AA Ferran, D Bibbal, T Pellet, M Laurentie, M Gicquel-Bruneau, ... International journal of antimicrobial agents 42 (5), 429-435, 2013 | 36 | 2013 |
| Differential activity of the combination of vancomycin and amikacin on planktonic versus biofilm-growing Staphylococcus aureus in a Hollow Fiber Infection Model DC Broussou, MZ Lacroix, PL TOUTAIN, F WOEHRLE, F EL GARCH, ... Frontiers in Microbiology 9, 572, 2018 | 34 | 2018 |
| Destruction of Staphylococcus aureus biofilms by combining an antibiotic with subtilisin A or calcium gluconate JJ Liu, JY Madec, A Bousquet-Mélou, M Haenni, AA Ferran Scientific reports 11 (1), 1-12, 2021 | 23 | 2021 |
| Comparison of in vitro static and dynamic assays to evaluate the efficacy of an antimicrobial drug combination against Staphylococcus aureus DC Broussou, PL Toutain, F Woehrlé, F El Garch, A Bousquet-Melou, ... PloS one 14 (1), e0211214, 2019 | 22 | 2019 |
| Comparison of the in vitro activity of five antimicrobial drugs on Staphylococcus pseudintermedius and Staphylococcus aureus biofilms AA Ferran, JJ LIU, A Bousquet-Mélou, PL TOUTAIN Frontiers in Microbiology 7, 1187, 2016 | 21 | 2016 |
| Maximum levels of cross‐contamination for 24 antimicrobial active substances in non‐target feed. Part 1: Methodology, general data gaps and uncertainties EFSA Panel on Biological Hazards (BIOHAZ), K Koutsoumanis, A Allende, ... EFSA Journal 19 (10), e06852, 2021 | 17 | 2021 |
| Infection-stage adjusted dose of beta-lactams for parsimonious and efficient antibiotic treatments: A Pasteurella multocida experimental pneumonia in mice MV Vasseur, MZ Lacroix, PL Toutain, A Bousquet-Melou, AA Ferran PloS one 12 (8), e0182863, 2017 | 15 | 2017 |
Alain Bousquet-MelouEcole Nationale Vétérinaire de Toulouse在 envt.fr 的电子邮件经过验证
